Future classes of hepatitis C virus therapeutic agents.
Recent advances in understanding of the molecular characteristics of the hepatitis C virus have led to the development of novel antiviral therapeutics. Direct-acting antivirals are designed to inhibit viral targets, whereas host-targeted antivirals block host factors that are used by the virus for its own life cycle. The rapid development of agents in multiple classes has led to the promise of shorter therapy duration, an improved side effect profile, and eventually interferon-sparing regimens. This article reviews novel hepatitis C virus therapeutics in development, including mechanism of action, efficacy, and adverse effects.
GI Unit, Massachusetts General Hospital, GRJ724, 55 Fruit Street, Boston, MA 02114, USA.
Jennifer Y
JY
Chen
Raymond T
RT
Chung
D000998:Antiviral Agents / Q000627:therapeutic use*; D016174:Hepacivirus / Q000302:isolation & purification* / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D054884:Host-Pathogen Interactions; D006801:Humans
D000998:Antiviral Agents